Liège-based sports tech company Myocene has secured an additional €3 million to further its growth, specifically focusing on the international commercialization of its innovative device across European and American markets.
Myocene’s cutting-edge device measures muscle fatigue objectively, providing a muscle fatigue index value in just two minutes. Utilizing a specialized algorithm, the device analyzes precise measurements gathered through a unique sensor and controlled muscle contractions. This versatile device can be used both indoors and outdoors, aiding elite athletes in managing fatigue and enhancing performance. It also supports strength and conditioning coaching by allowing for tailored training sessions and rest periods, helping to prevent overtraining and injury.
“Since our last funding round in March 2023,” stated CEO Jean-Yves Mignolet, “we have secured contracts with top European soccer clubs like OGC Nice, Sporting Club Braga, and Paris-Saint Germain. During this period, over 850 athletes have used our device during training sessions, resulting in more than 10,500 measurements. These measurements have enabled fitness trainers to make informed decisions about player training and have helped us refine our device and improve user protocols, confirming the data’s reliability.”
The recent €3 million fundraising, involving InvestSud, Wallonie Entreprendre, Noshaq, and the company’s founders, includes both capital and a convertible loan. This funding will accelerate the product’s commercialization in Europe and the United States.
“The Myocene device signifies a significant advancement in athlete monitoring,” said Dr. Pierre Rigaux, Chairman and Founder. “The tests since our launch have established our technology as a benchmark for measuring muscle fatigue in athletes. With this new funding, we are poised for growth in Europe and the launch of Myocene in the US market in 2025, which we approach with great optimism,” he concluded.
